Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets
<strong>Background:</strong> Nevirapine is the only non-nucleoside reverse transcriptase inhibitor currently available as a paediatric fixed-dose combination tablet and is widely used in African children. Nonetheless, the number of investigations into pharmacokinetic determinants of viro...
Main Authors: | Bienczak, A, Denti, P, Cook, A, Wiesner, L, Mulenga, V, Kityo, C, Keketiinwa, A, Gibb, D, Burger, D, Walker, A, McIlleron, H |
---|---|
Format: | Journal article |
Published: |
Lippincott, Williams & Wilkins
2017
|
Similar Items
-
The effect of diurnal variation, CYP2B6 genotype, and age on the pharmacokinetics of nevirapine in African Children
by: Bienczak, A, et al.
Published: (2016) -
Plasma efavirenz exposure, sex, and age predict virological response in HIV-infected African children.
by: Bienczak, A, et al.
Published: (2016) -
Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets.
by: L'homme, R, et al.
Published: (2008) -
Pharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets.
by: Fillekes, Q, et al.
Published: (2012) -
Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
by: Oudijk, J, et al.
Published: (2012)